Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
News
TYPE
HEADLINE
FILED AT
6-K
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill’s Crohn’s Disease Candidate
6-K
Company Regains Worldwide RHB-102 Rights After Terminating Ex-North America License Agreement With $200,000 Break-Up Fee
6-K
$2.9 Million NCI Grant Awarded to University of Oklahoma for Clinical Trials of RedHill’s Opaganib in Combination with CAR T-Cell Therapy for Ultra-High-Risk Mu
6-K
RedHill Biopharma Files Prospectus Supplement to Increase At The Market Offering
6-K
RedHill Biopharma Granted Additional 180-Day Period by Nasdaq to Regain Minimum Bid Price Compliance
6-K
RedHill Biopharma Announces Sale of Talicia Holdings Interest, License Agreement with Ferring, and Stockholders' Equity Update
November 2025 ATM | Offering amount: $352,267 | Amount sold to date: $3,400,000 | Float: 45,431,767,690
Registrations
TYPE
HEADLINE
FILED AT
F-3
SHARE RESALE REGISTRATION
POS AM
Form POS AM - Post-Effective amendments for registration statement
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
F-1/A
YA - SPA - Under the Standby Equity Purchase Agreement, ADSs are sold to YA in discrete “advances,” with the per-share price for each advance tied to the market price of the ADSs at the time the advance notice is delivered. The exact number of ADSs included in any advance is selected by the Company and is limited to the shares it has authorized and available for issuance. The parties have also agreed to ownership limits that prevent YA from exceeding a specified percentage of the Company’s outstanding ADSs.
F-1
YA II - SPA - Under the Purchase Agreement we may require YA to buy up to $25.0 million of ADSs through multiple “Advances” delivered at our discretion during the commitment period. The purchase price for each advance is tied to the prevailing market price of the ADSs at the time of the advance and is calculated under the formula in the agreement, giving YA a discounted price to market. We have registered 6,465,559 ADSs for resale, and the agreement caps both the size of any single advance and YA’s total ownership so that its beneficial stake does not exceed the agreed-upon threshold. If market prices fall, we would need to issue additional ADSs (under a future registration) to obtain the full $25 million, which could create further dilution.
POS AM
Form POS AM - Post-Effective amendments for registration statement
